Reply To: Traders Market Weekly: Incoming Deluge of Central Bankers

13 Sep '23 at 9:51 am #65368
Truman
Participant

Rocket Pharmaceuticals (RCKT 18.70, +3.41, +22.3%): Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease; prices offering of 7,812,500 shares of its common stock at $16.00 per share and pre-funded warrants to purchase 3,126,955 shares of common stock at $15.99 per pre-funded warrant